THERAPY DOSSIER · th-2aae48281810

comb1 peptide (tenascin X and fibrillin 1 fragments) and UN3 peptide (platelet-rich plasma derived)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22384158 ↗2012Reported benefit

Human platelet-rich plasma- and extracellular matrix-derived peptides promote impaired cutaneous wound healing in vivo.

MouseWoundBALB/cn = 9 to 15 animals per treatment group (3-5 animals per group…Topical to the wound, injected under the dressings using a 25G needle1 mg/mL comb1 and 284 microgram/mL UN3, suspended in 3% car…From 24 h after injury

Model: Cranial dermal wounds in mice treated with cyclophosphamide to impair wound healing

comb1 and UN3, alone and combined, improved epithelialisation, granulation tissue and collagen deposition and roughly doubled wound vessel density in impaired wounds.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…